Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026

Two scientific presentations highlight next-generation innovation and patient outcomes with total artificial heart support TUCSON, Ariz., June 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard Medical” or the "Company”), parent company of SynCardia Systems, LLC ("SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, today announced that SynCardia researchers will present new preclinic